This site is intended for healthcare professionals

Immunocore announces UK MHRA accepts MAA for tebentafusp in metastatic uveal melanoma.

Read time: 1 mins
Last updated:9th Sep 2021
Published:9th Sep 2021
Immunocore announces that United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted a Market Authorisation Application (MAA) seeking the approval of tebentafusp (IMCgp100) for the treatment of patients with metastatic uveal melanoma (mUM).
Condition: Metastatic Uveal Melanoma,
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest